Planta Med 2008; 74 - PA305
DOI: 10.1055/s-0028-1084303

Properties of concentrated Bio-extract of noni – Thai „yor“ Morinda citrifolia

P Nandhasri 1, S Thamaree 2, T Punjanon 3, S Kietinun 1
  • 1Applied Thai Traditional Medicine, Faculty of Medicine, Thammasat University, Patumthani 12120, Thailand
  • 2Pharmacology Department, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
  • 3Pharmacology and Toxicology Unit, Faculty of Science, Rangsit University, Patumthani 12000, Thailand

The properties of concentrated bio-extract of Thai „Yor“ (BCTY), Yor or Noni, Morinda citrifolia, are reported concerning quality and quantity analysis. HPLC and TLC methods were used for vitamins and phytochemicals study respectively. The average value of solid content, protein, fat, ash, and calories in 100g of the BCTY have been found 16.82, 0.51, 0.55, 0.01g and 69.79 calories respectively. Minerals determination including sodium, potassium, calcium, iron and selenium have been reported with the content of 83.65, 227.58, 186.65, 4.068 and ≤0.0035µg/g respectively. By HPLC method, the average content of vitamins C, B1, B2, B3 and B12 in 100g juice were 97.63, 45.64, 42.56, 58.45 and 38.53mg respectively and the total of 17 amino acids were 204mg/100g (range 2.00–34.90mg/100g). Determination by TLC has shown the quality of anti-oxidants, alkaloids, saponnins, scopoletin, anthraquinones, flavonoids and essential oils. The BCTY quality is free from microorganisms: yeast-mold and total bacterial counts, Clostridium perfringents, Staphylococcus aureus and Bacillus cereus and safely consumed in the recommended amount of 30ml/day, before meal. The BCTY is nontoxic with the acute toxicity, LD 50, of more than 5,000mg/kg body weight of Swiss albino mice and Wistar rat. The methyl alcohol extract of M. citrifolia raw material which is used for producing the BCTY has shown an analgesic effect equivalent to morphine sulfate. A positive result for immune activity has been shown for this BCTY product [1]. BCTY also showed 29.07% inhibition for the reverse transcriptase activity of the HIV-1SUM9.

Reference: 1. Giorgi, J.V., Hultin, (1990) Clin Immunol Newslett 10:5561.